Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug entry refers to a specific triple-combination analgesic regimen investigated by **Tanta University** for the management of postoperative pain in patients undergoing lower limb orthopedic surgery. The regimen is administered epidurally and consists of the local anesthetic **bupivacaine**, the alpha-2 adrenergic agonist **clonidine**, and the synthetic opioid **meperidine** (also known as pethidine). Bupivacaine provides regional anesthesia by inhibiting voltage-gated sodium channels, thereby blocking nerve impulse conduction. Clonidine acts as an adjuvant that enhances and prolongs the sensory and motor block by stimulating alpha-2 adrenergic receptors in the spinal cord. Meperidine serves as a mu-opioid receptor agonist, providing additional regional and systemic analgesia. Clinical trial data suggests that this combination offers prolonged postoperative analgesia and superior hemodynamic stability compared to similar regimens using fentanyl.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + clonidine + meperidine.